pancreatic cancer
Conditions
Interventions
Case series:nab-paclitaxel plus S-1 as neoadjuvant therapy
Sponsors
Department of Hepato-pancreato-biliary surgical oncology, Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 70 years old male and female; 2. Preoperative diagnosis of pancreatic ductal adenocarcinoma was confirmed based on clinical symptoms, imaging examinations, tumor markers and other auxiliary examinations or biopsy results; 3. According to the NCCN guideline (2017 V3), the inclusion PDAC is borderline resectable pancreatic cancer via preoperative imaging examinations. Arterial status: Pancreatic head or uncinate process: solid tumor contact with common hepatic artery (CHA) without extension to celiac axis or hepatic artery bifurcation allowing for safe and complete resection and reconstruction; solid tumor contact with the SMA of =180 degree; solid tumor contact with variant arterial anatomy (ex: accessory right hepatic artery, replaced right hepatic artery, replaced CHA and the origin of replaced or accessory artery) and the presence and degree of tumor contact should be noted if present. Pancreatic body/tail: solid tumor contact with the celiac axis (CA) of =180 degree; solid tumor contact with the CA of >180 degree without involvement of the aorta and with intact and uninvolved gastroduodenal artery. Venous status: solid tumor contact with the SMV or PV of >180 degree, contact of =180 degree with contour irregularity of the vein or thrombosis of the vein but with suitable vessel proximal and distal to the site of involvement allowing for safe and complete resection and vein reconstruction; solid tumor contact with the inferior vena cava(IVC); 4. Participate in the study voluntarily and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. With other system malignant tumor; 2. Accept any form of anti-tumor treatment 5 weeks before grouping randomly, including intervention, ablation, radiotherapy, chemotherapy and molecular targeted therapy, etc.; 3. Using any study drug in other clinical trials 5 weeks before grouping randomly; 4. With any central nervous system disease, mental disease, unstable angina, severe congestive heart failure, arrhythmia or other serious diseases which cannot be control; 5. With allergy history of clinical trial drugs or similar structure drugs; 6. Lactating or pregnant; 7. Any situation which could damage patient safety or the integrity of the data,including severe medical risk factors, medical conditions, and laboratory abnormalities; 8. immunosuppressive patients; 9. The researchers considered it inappropriate to participate in the experiment; 10. Patients are unwilling or unable to comply with the program, or loss to follow-up for more than 1 course during treatment. such as HIV positive.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| R0 resection rate;Disease-free survival, DFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;colligation condition during operation;safety profile;Quality of Life Assessment; | — |
Countries
China
Contacts
Public ContactLiu Rong
Chinese PLA General Hospital
Outcome results
None listed